The Role Of MESNA: sodium 2-mercaptoethanesulfonat In Prevention Of Contrast – Medium Induced Nephropathy

Abstract

Background & Aim: Contrast-induced nephropathy is the third most common cause of hospital acquired renal failure, after decreased renal perfusion and nephrotoxic medications. There are many risk factors considered to be associated with the development of Contrast-induced nephropathy (CIN), so there have been a lot of preventive strategies. One of the new strategies is use of MESNA (sodium 2-mercaptoethanesulfonat) before investigations that require radiographic contrast agents.

This study aim to Prevention of contrast-induced nephropathy in at-risk patients given radiographic contrast agents.

Materials and Methods; This is a retrospective cohort study in which we followed 740 patients who undergone investigations that required radio-graphic contrast agents for five years and collected these data: risk factors of CIN (diabetes mellitus, chronic kidney disease GFR ≤ 60 ml/min/1.73m², age ≥ 75 years, congestive heart failure EF ≤ 35, volume of radiographic contrast agent, type of investigation required), baseline serum creatinine level before contrast medium use, serum creatinine level after 24-48-72 hours following the use of radio-graphic contrast agents.

Results:  The incidence of Contrast-induced nephropathy (CIN) was 0.7% (5 patients).  

Conclusion; MESNA plus volume expansion before and during contrast exposure was effective for preventing CIN compared to volume expansion alone.